OTCPicks.com: OTCPicks.com Daily Market Movers Digest Midday Report for Wednesday, September 3rd AGMS, CPRK, NBIX, MONA

Wed. September 03, 2008; Posted: 11:47 AM

Visit http://www.otcpicks.com to register for our Daily Market Mover's Digest Newsletter and Email Stock Watch Alerts.

ANGSTROM MICROSYSTEMS CORPORATION (OTCBB: AGMS)

Detailed Quote: www.otcpicks.com/quotes/AGMS.php

Company Profile: http://www.otcpicks.com/angstrom-microsystems/angstrom-microsystems.htm Angstrom Microsystems is one of the top Green computing companies, providing technology solutions ranging from liquid-cooled blades to acceleration software in order to help reduce the power requirements of datacenters. Its customers include Rhythm & Hues, Fox Films, Tippett Studios and the National Institutes of Health. Angstrom has earned a reputation for quality, service, and engineering innovation in the AMD Opteron processor-based system market. See Angstrom Microsystems in the end credits of Blue Sky Studios' "Ice Age: The Meltdown."

AGMS News:

September 3 - Angstrom Microsystems Acceleration Software Uses Gaming Technology to Save Data Centers Energy

Faster Servers Mean Fewer Servers Needed, Saving Overall Power Usage in the $15 Billion High Performance Computing (HPC) Market

Angstrom Microsystems Corp. (OTCBB: AGMS | Quote | Chart | News | PowerRating) is a market leader in "Green Computing" solutions. Angstrom's Xfactor Plus(TM) acceleration software saves energy within data centers by reducing the number of machines needed to run certain computation-intensive calculations for various types of applications, hence saving air conditioning and electricity in the data center. A report by the EPA dated August 2007 indicates the severe nature of the power and air-conditioning problem befalling data centers around the U.S.

Typically used by video game enthusiasts, high-end graphics cards (Graphic Processing Units - GPUs) drive Angstrom's software, providing plug-and-play ultra-fast solutions for the HPC market. As commercial off-the-shelf (COTS) components, GPUs are critical to Angstrom's success by driving down hardware costs for comparable computations, while providing a path to compatibility with existing customer software.

Xfactor Plus provides speed increases between 10x and 100x depending on the application or library being accelerated and is fully compatible with existing software. An Increase in performance per computer often leads to a reduction in their numbers, saving data center resources that would have otherwise been spent on inefficient computing.

Angstrom's Xfactor Plus software acceleration solutions are geared towards a variety of vertical market segments including high performance computing, life sciences, movie special effects and animation rendering, oil and gas applications, design and automation, broadcast applications and Internet multi-media.

"Angstrom was recently first-to-market with the popular FFTW (Fast Fourier Transform) compatible library solution based on the core Xfactor Plus technology," said Lalit Jain, CEO of Angstrom Microsystems. Mr. Jain continues, "Our Xfactor Plus 'FFTW' library has been very successful, and we are actively working on many other software acceleration solutions to address a variety of other high-end vertical market server applications."

Xfactor Plus is sold as a stand-alone package that can be installed on existing Linux-based computers and as a turnkey solution installed on Angstrom hardware.

COPPER KING MINING CORPORATION (OTC: CPRK)

Detailed Quote: www.otcpicks.com/quotes/CPRK.php

Company Profile: www.otcpicks.com/copper-king-mining/copper-king-mining.htm

Copper King Mining Corporation currently owns approximately 1200 acres in the Drum Mountains of Utah, which are patent deeded mining claims which contain gold, silver and copper. The company recently added to its holdings by filing six more claims on land which was inside their holdings, but not patent deeded. Contiguous to that acreage is approximately 1100 acres of claims filed by Western Utah Copper Company. As the companies explored the concept of a joint venture on the Drum Mountain properties, it was decided that a very viable consideration was to join the total assets of both companies.

CPRK News:

September 3 - Copper King Mining Corporation Announces Bridge Funding

Copper King Mining Corporation (OTC: CPRK), an ore mining, processing, and exploration company located in Southern Utah, announced that it closed on bridge funding with a third party lender.

Copper King today announced that it closed a private transaction on Friday, August 29, 2008, for bridge funding that is associated with its anticipated permanent bond financing. The company affirmed that the bridge funding was completed by a third party investor in a related industry; that the terms of the financing are favorable to the company; and that no equity was involved in the transaction.

The company anticipates using the bridge funding to complete construction of its state-of-the-art Flotation Mill near Milford, Utah.

NEUROCRINE BIOSCIENCES INCORPORATED (NASDAQ: NBIX | Quote | Chart | News | PowerRating) "Up 8.21% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/NBIX.php

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome (IBS), anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH) and other neurological and endocrine related diseases and disorders. For more information, visit www.neurocrine.com.

NBIX News:

September 2 - Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis

Phase II Study Meets Primary Bone Mineral Density and Secondary Efficacy Endpoints

Neurocrine Biosciences, Inc. (Nasdaq: NBIX | Quote | Chart | News | PowerRating) announced positive safety and efficacy results from its third Phase II clinical trial using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis. The PETAL study enrolled 252 patients, with a confirmed diagnosis of endometriosis, into three treatment groups; elagolix 150 mg once daily, elagolix 75 mg twice daily, or depo-subQ provera 104(TM) (DMPA) for six months of treatment.

The primary endpoint for the PETAL study was the percent change from baseline in mean bone mineral density (BMD) at Month 6 measured via dual energy X-ray absorptiometry (DXA). Pursuant to discussion with the FDA, the pre-specified statistical analysis plan sought to demonstrate that at Month 6, the lower bound of the 95% confidence interval did not exceed a -2.2% change in BMD from baseline. In women randomized to elagolix 150 mg once daily, the mean percent change from baseline at Month 6 was -0.11% for the spine (lower bound -0.70%) and -0.47% for the femur (lower bound -0.96%). The mean percent change from baseline at Month 6 for the elagolix 75 mg twice daily dosing arm was -1.30% for the spine (lower bound -1.86%) and -0.99% for the femur (lower bound -1.46%).

"The PETAL study demonstrates that elagolix did not induce significant bone loss over a six month treatment of patients with endometriosis, while providing both rapid and significant pain reduction in endometriosis symptoms," said Chris O'Brien, MD, Chief Medical Officer at Neurocrine. "Additionally, this study confirms our decision to move forward with once daily dosing."

Secondary endpoints for the PETAL study were evaluated to assess the improvement of endometriosis symptoms following treatment with elagolix. Improvement in endometriosis symptoms was documented using several different scales for endometriosis pain. The following were assessed before, during and after the six months of treatment:

* Total Composite Pelvic Sign and Symptoms Score (CPSSS), a validated 0-15 scale that assesses five components of endometriosis pain severity, each on a 0-3 scale.

* Dysmenorrhea (pelvic pain during menstruation), a component of the CPSSS; 0-3 scale (0=absence of pain, 1=mild pain, 2=moderate pain, 3=severe pain).

* 98% of patients at baseline had moderate or severe dysmenorrhea.

* Non-menstrual pelvic pain (pelvic pain outside of menstruation), a component of the CPSSS; 0-3 scale (0=absence of pain, 1=mild pain, 2=moderate pain, 3=severe pain).

* 97% of patients at baseline had moderate or severe non-menstrual pelvic pain.

* Responder Rate, percentage of patients who had a one point or greater decrease in pain score.

* Visual Analog Scale (VAS) to assess pelvic pain levels using daily electronic diary.

Elagolix provided a clinically meaningful and statistically significant reduction in endometriosis pain from baseline as shown below. The magnitude of improvement is comparable to that demonstrated with the currently approved agents, leuprolide and DMPA.

"We have treated over 600 subjects with elagolix in our extensive endometriosis clinical program, and have consistently seen a robust reduction in endometriosis pain using multiple outcome measures. In our previous Phase II studies we have shown rapid onset of action and sustained efficacy over three months. This study extends those findings, demonstrating significant and sustained pain reduction for six months," said Dr. O'Brien. "There is much more data to come from this study once patients complete the six month follow-up and the study is unblinded at an individual patient level. At that time we will be able to make correlations between pain scores, BMD, pharmacokinetic values, and hormonal levels on an individual patient basis, and we look forward to also sharing those results, as soon as they are available."

Treatment with elagolix was also safe and generally well tolerated. Discontinuation from the clinical trial due to adverse events (AE) was more common among women randomized to DMPA (16%) than those receiving elagolix 150 mg once daily (5%) or 75 mg twice daily (7%). This increased discontinuation in women randomized to DMPA was primarily attributable to irregular vaginal bleeding. The overall rate of AE reporting was comparable across all groups. The most common AE was headache; this was reported 35 times by 19 women (23%) randomized to elagolix 150 mg once daily, 52 times by 22 women (26%) randomized to elagolix 75 mg twice daily, and 43 times by 12 (14%) women randomized to DMPA. There were two serious AEs that led to discontinuation from the trial, both in the DMPA group. The mean frequency of hot flashes was comparable in both the screening period and the treatment period, approximately 0.5 per day across all treatment groups, consistent with our prior Phase II studies.

"We couldn't be more pleased with the results of this study," said Kevin C. Gorman, President and Chief Executive Officer, Neurocrine Biosciences. "We began this program nine years ago with the hope of selectively modulating the GnRH system with an oral antagonist. This trial and our previous Phase II studies have now shown that this is possible. Elagolix is a first in class drug for endometriosis sufferers who desperately need a safe and effective therapy. This is apparent from the 8,000 inquiries to the call center for just this one study. Additionally, to date we had more than 6,000 inquiries regarding the ongoing Lilac PETAL study which is now fully enrolled and on track to report results in 2009."

"These study results are very encouraging," said Shayne M. Plosker, MD, Associate Professor and Division Director, of USF IVF and Reproductive Endocrinology at the University of South Florida College of Medicine in Tampa. "Elagolix has the potential to be an ideal advanced medical therapy for endometriosis-associated pelvic pain and dysmenorrhea. Intermediate suppression of estradiol by a well-tolerated drug appears attainable affording endometriosis symptom reduction without bone loss."

MONARC CORPORATION (OTC: MONA | Quote | Chart | News | PowerRating) "Up 50.00% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/MONA.php

Monarc Corporation was formed in 2000. The company acquired multiple subprime short term lending companies for the B2C marketplace doing business under the brand name "Cash Now" in 2003. The company also had an array of other financial products such as IFGX and Cash Next under development for the B2B marketplace; such as invoice discounting and factoring. In 2005 the company suffered a setback with 4 consecutive strikes of hurricanes of 2005 while domiciled in Florida. Unable to operate on a day to day basis without interruptions, the company was delisted from being am SEC reporting issuer soon after and consequently its stock was re-ranked as an unsolicited stock and 2006 was a reconstructing year. The company used the time out to raise capital with the issuance of preferred convertible shares. Soon after, in January 2007, it resumed operations. With the sweeping changes in the subprime industry and with most of the States and Provinces restricting this product use the company looked at different industries. In 2007, it launched a Check 21 product and a Forex division and looked towards China as a growth market. In late 2007 MONA sold these aforementioned operating assets to a China-based company and the proceeds of that sale were distributed to its shareholders. In early 2008, MONA looked for another growth industry and decided to enter beverage control. The company acquired 3 start-up entities in the hospitality control industry. In December 2007, the controlling interest of Monarc was purchased by Brookcor Holdings, on an all cash and stock basis. Those businesses were spun out several months later and the paid stock returned to the treasury. MONA identified a China-based mass distribution company and completed a reverse merger with them through their Belize holding company Fulushu Limited in June 2008. The company continues operating these entities as it nears completion of the development of its B2B product line. The company is also currently in a process of filing certain documents to remove the warning sign from the Pink Sheets quotation system and to again become a solicited company, with future plans on becoming an SEC reporting issuer. MONA is also taking measures to raise the pink sheets ranking from "Yield limited information" to a "pink check mark status."

MONA News:

September 2 - MonArc Corporation Announces Change Of Corporate Direction

MonArc Corporation (OTC: MONA | Quote | Chart | News | PowerRating) (www.monacorporation.com) announced that it is in the process of liquidating certain assets, and operating subsidiaries to 2 or possibly 3 different buyers.

Once the aforementioned sale of assets transaction is completed MONA would itself be bought out on all cash basis by a Chinese based Direct Marketing Company MCD. MCD intends to fully complete the Corporate Compliance to achieve a solicited issuer status. MCD is also desirous to add its 7,000 plus current shareholder base to MONA.

In the unlikely event for whatever reason this Corporate Compliance threshold cannot be met then the issuer intends to amend its corporate resolution to become a USA based Special Purpose Acquisition Company (SPAC).

One of the unique characteristics that MONA can offer is a constant dividend to its shareholders in all of these various China based companies.

The issuer has filed a comprehensive Corporate Update Filing on Pink Sheets, which can be viewed by visiting this link directly:

http://www.pinksheets.com/otciq/ajax/showFinancialReportById.pdf?id=1694 5

MONA management believes that it is an excellent candidate to be a SPAC Company. With these aforementioned asset sales and spin outs it would represent 3 separate dividend payouts in 2008 for the issuer.

ABOUT OTCPICKS.COM

OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has been compensated seventy five thousand free trading shares by a third party, non-controlling shareholder (Richard Hue) for AGMS advertising and promotional services. OTCPicks.com has been compensated sixteen thousand five hundred dollars by a third party for CPRK advertising and promotional services. For a complete list of disclosures go to http://www.otcpicks.com/disclosure-details.htm . The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.

The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.

Third Party Web Sites and Information:

OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.

CONTACT: Brian Dean, Publisher, OTCPicks.com Tel: +1 972 546 3740 e-mail: publisher@otcpicks.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details for AGMS click here.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index